NCT01371214

Brief Summary

The primary goal of this study is to perform a 36-week pilot study with a cross-over design to study the safety and efficacy of a novel integrative exercise program called PLIÉ (Preventing Loss of Independence through Exercise). PLIÉ integrates elements of Eastern and Western exercise traditions and is specifically designed to target the muscles and movements needed to help individuals with mild-to-moderate dementia maintain physical function and independence.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for phase_1

Timeline
Completed

Started Jun 2011

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2011

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

June 7, 2011

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 10, 2011

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2012

Completed
Last Updated

June 3, 2015

Status Verified

June 1, 2015

Enrollment Period

1.3 years

First QC Date

June 7, 2011

Last Update Submit

June 2, 2015

Conditions

Keywords

exerciseexercise movement techniquesactivities of daily living

Outcome Measures

Primary Outcomes (10)

  • Change in physical function (participant)

    Participant's physical function will be assessed with the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) scale (Galasko 1997). The ADCS-ADL is a 78-point scale that assesses functional ability in 23 daily activities based on informant report. It is the standard measure for assessment of functional status in AD treatment trials.

    Baseline, 18 weeks, 36 weeks

  • Change in quality of life (participant)

    Quality of life will be assessed with the Quality of Life Scale in Alzheimer's Disease (QOL-AD), which is a brief, 13-item measure that obtains input from both the individual and the caregiver (Logsdon 1999). Scores may range from 13-52 points.

    Baseline, 18 weeks, 36 weeks

  • Change in functional health and well-being (participant)

    Functional health and well-being will be assessed with the SF-36v2, which assesses function in eight domains and provides physical and mental component summary scores that may range from 0 to 70 (Stewart 1989). The SF-36v2 is typically administered directly to participants. However, we also will ask caregivers to answer questions on behalf of participants and will compare their answers to assess congruence. Data collected will help to determine if this measure is suitable for a larger trial.

    Baseline, 18 weeks, 36 weeks

  • Change in number of falls (participant)

    Participant's falls will be assessed based on caregiver report.

    Baseline, 18 weeks, 36 weeks

  • Change in fall-related self-efficacy (participant)

    Fall-related self-efficacy will be assessed with the Falls Efficacy Scale (FES), which is a 10-item scale that has been validated in individuals with cognitive impairment (Hauer 2010).

    Baseline, 18 weeks, 36 weeks

  • Change in physical performance (participant)

    Physical performance will be assessed with the Short Physical Performance Battery (SPPB), which was developed by the National Institute on Aging to provide an objective tool for evaluating lower extremity functioning in older adults. The test includes repeated chair stands, tandem balance testing and 8' walking speed (Guralnik 1994).

    Baseline, 18 weeks, 36 weeks

  • Change in cognitive function (participant)

    Cognitive function will be assessed with the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) (Rosen 1984), which is the most commonly used primary outcome measure in AD treatment trials. It is an 80-point scale that includes direct assessment of learning (word list), naming (objects), following commands, constructional Praxis (figure copying), ideational Praxis (mailing a letter), orientation (person, time, place), recognition memory and remembering test instructions.

    Baseline, 18 weeks, 36 weeks

  • Compliance (participant)

    Participant compliance will be determined based on % of exercise classes attended from baseline to 18 weeks and from 18-36 weeks.

    Baseline, 18 weeks, 36 weeks

  • Adverse events (participant)

    Number of adverse events from baseline to 18 weeks and from 18 weeks to 36 weeks will be monitored through biweekly telephone calls with caregivers.

    Baseline, 18 weeks, 36 weeks

  • Change in dementia-related behaviors (participant)

    Participant's dementia-related behaviors will be assessed with the Neuropsychiatric Inventory (NPI), which is a 144-point informant-based questionnaire that assesses 12 behavioral domains common in dementia including frequency, severity and impact on caregiver distress (Cummings 1997).

    Baseline, 18 weeks, 36 weeks

Secondary Outcomes (2)

  • Change in functional health and well-being (caregiver)

    Baseline, 18 weeks, 36 weeks

  • Change in burden (caregiver)

    Baseline, 18 weeks, 36 weeks

Study Arms (2)

Group 1

EXPERIMENTAL

PLIÉ exercise program 30-45 minutes, 2-3 days/week for 18 weeks followed by 18 weeks of usual care (20-minutes of chair-based exercises 2-5 days/week).

Behavioral: PLIÉ (Preventing Loss of Independence through Exercise)

Group 2

ACTIVE COMPARATOR

Usual care (20 minutes of chair-based exercises 2-5 days/week) for 18 weeks followed by the PLIÉ exercise program 30-45 minutes/day, 2-3 days/week for 18 weeks.

Behavioral: PLIÉ (Preventing Loss of Independence through Exercise)

Interventions

Integrative exercise program that incorporates elements of Eastern and Western exercise traditions to target the muscles and movements needed to help individuals with mild to moderate dementia maintain functional status and independence.

Group 1Group 2

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Current participant in the Irene Swindells Center for Adult Day Services in San Francisco, CA
  • Recommended by Swindells staff
  • mild-to-moderate dementia
  • caregiver consent
  • Provide care to primary participant in the Irene Swindells Center for Adult Day Services in San Francisco, CA
  • can provide information about the primary participant's physical functioning, behaviors, falls, quality of life and own level of stress.

You may not qualify if:

  • major current psychiatric illness (e.g., schizophrenia, bipolar disorder)
  • life expectancy \< 1 year (e.g., metastatic cancer)
  • inability to assent to study procedures
  • Any major neurologic disease (e.g., dementia, stroke, Parkinson's disease, ALS)
  • major current psychiatric illness (e.g., schizophrenia, bipolar disorder)
  • life expectancy \< 1 year (e.g., metastatic cancer)
  • evidence of cognitive impairment
  • inability to consent to study procedures.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Irene Swindells Center for Adult Day Services, Institute on Aging

San Francisco, California, 94118, United States

Location

Related Publications (2)

  • Barnes DE, Mehling W, Wu E, Beristianos M, Yaffe K, Skultety K, Chesney MA. Preventing loss of independence through exercise (PLIE): a pilot clinical trial in older adults with dementia. PLoS One. 2015 Feb 11;10(2):e0113367. doi: 10.1371/journal.pone.0113367. eCollection 2015.

  • Wu E, Barnes DE, Ackerman SL, Lee J, Chesney M, Mehling WE. Preventing Loss of Independence through Exercise (PLIE): qualitative analysis of a clinical trial in older adults with dementia. Aging Ment Health. 2015;19(4):353-62. doi: 10.1080/13607863.2014.935290. Epub 2014 Jul 14.

MeSH Terms

Conditions

DementiaMotor Activity

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesNeurocognitive DisordersMental DisordersBehavior

Study Officials

  • Deborah E Barnes, PhD, MPH

    University of California, San Francisco

    PRINCIPAL INVESTIGATOR
  • Margaret Chesney, PhD

    University of California, San Francisco

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor, Psychiatry and Epidemiology & Biostatistics

Study Record Dates

First Submitted

June 7, 2011

First Posted

June 10, 2011

Study Start

June 1, 2011

Primary Completion

September 1, 2012

Study Completion

September 1, 2012

Last Updated

June 3, 2015

Record last verified: 2015-06

Locations